Ubs Group Ag Altimmune, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Altimmune, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 282,455 shares of ALT stock, worth $2.33 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

282,455

Previous 159,601 76.98%

Holding current value

$2.33 Million

Previous $1.06 Million 63.43%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$5.5 - $8.1 $675,697 - $995,117	122,854 Added 76.98%	282,455 $1.73 Million
Q2 2024 Aug 13, 2024	SELL	$5.91 - $10.23 $1.95 Million - $3.38 Million	-330,400 Reduced 67.43%	159,601 $1.06 Million
Q1 2024 May 13, 2024	BUY	$8.22 - $13.81 $3.55 Million - $5.96 Million	431,741 Added 741.06%	490,001 $4.99 Million
Q4 2023 Feb 09, 2024	BUY	$2.14 - $11.62 $72,768 - $395,126	34,004 Added 140.19%	58,260 $655,000
Q3 2023 Nov 09, 2023	BUY	$2.4 - $3.45 $13,665 - $19,644	5,694 Added 30.68%	24,256 $63,000
Q2 2023 Aug 11, 2023	SELL	$3.45 - $5.97 $495,544 - $857,506	-143,636 Reduced 88.56%	18,562 $65,000
Q1 2023 May 12, 2023	SELL	$4.19 - $16.83 $925,449 - $3.72 Million	-220,871 Reduced 57.66%	162,198 $684,000
Q4 2022 Feb 08, 2023	BUY	$8.74 - $16.45 $2.86 Million - $5.38 Million	326,792 Added 580.68%	383,069 $6.3 Million
Q3 2022 Nov 10, 2022	BUY	$10.67 - $22.41 $595,055 - $1.25 Million	55,769 Added 10978.15%	56,277 $718,000
Q2 2022 Aug 10, 2022	SELL	$3.94 - $11.77 $5,910 - $17,655	-1,500 Reduced 74.7%	508 $6,000
Q1 2022 May 16, 2022	SELL	$5.9 - $9.45 $1.02 Million - $1.63 Million	-172,840 Reduced 98.85%	2,008 $12,000
Q4 2021 Feb 14, 2022	BUY	$8.69 - $12.48 $635,291 - $912,362	73,106 Added 71.85%	174,848 $1.6 Million
Q3 2021 Nov 15, 2021	BUY	$8.43 - $16.81 $569,505 - $1.14 Million	67,557 Added 197.62%	101,742 $1.15 Million
Q2 2021 Aug 13, 2021	SELL	$9.85 - $16.46 $567,773 - $948,787	-57,642 Reduced 62.77%	34,185 $337,000
Q1 2021 May 12, 2021	SELL	$12.71 - $24.31 $16.6 Million - $31.8 Million	-1,309,863 Reduced 93.45%	91,827 $1.3 Million
Q4 2020 Feb 11, 2021	BUY	$7.84 - $14.22 $11 Million - $19.9 Million	1,400,483 Added 116030.07%	1,401,690 $15.8 Million
Q3 2020 Nov 12, 2020	SELL	$9.93 - $33.26 $361,829 - $1.21 Million	-36,438 Reduced 96.79%	1,207 $16,000
Q2 2020 Jul 31, 2020	BUY	$2.9 - $10.71 $107,720 - $397,822	37,145 Added 7429.0%	37,645 $403,000
Q1 2020 May 01, 2020	SELL	$1.69 - $3.8 $4,446 - $9,997	-2,631 Reduced 84.03%	500 $2,000
Q4 2019 Feb 14, 2020	BUY	$1.53 - $2.15 $4,131 - $5,805	2,700 Added 626.45%	3,131 $6,000
Q3 2019 Nov 14, 2019	SELL	$1.95 - $2.66 $1,934 - $2,638	-992 Reduced 69.71%	431 $1,000
Q2 2019 Aug 14, 2019	BUY	$2.19 - $3.4 $3,116 - $4,838	1,423 New	1,423 $3,000
Q1 2019 May 14, 2019	SELL	$2.54 - $4.54 $1,602 - $2,864	-631 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$1.72 - $7.24 $1,085 - $4,568	631 New	631 $1,000

Others Institutions Holding ALT

# of Institutions

186

Shares Held

39.3M

Call Options Held

913K

Put Options Held

743K

View Full List

About Altimmune, Inc.

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $404M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

More about ALT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account